T1	Participants 52 78	superficial bladder cancer
T2	Participants 323 344	patients with primary
T3	Participants 345 419	or recurrent superficial bladder tumors, including carcinoma in situ (CIS)
T4	Participants 840 880	ecurrence rate of tumors in 308 patients
T5	Participants 975 1057	13 (16.7%) of 78 BCG-treated patients and in 12 (13.8%) of 87 MMC-treated patients
